The 'Dispatched' Podcast

Congratulations to one of Australia's leading health journalists on a highly effective series of stories and commentaries that reveal the true extent of this country's challenge and the problems patients face in accessing medicines. A welcome hardening of the research-based industry's public position on the need for change, a very good report on a needed health technology, and another 'cheap' outcome for patients.

Why long-term thinking and planning are the key to success. What is the ten-year goal, and how does a new agreement progress that? Plan for policy and government engagement like it's a product launch. Also, is the problem with the HTA Review the process or the expectation? How a different starting point would have made this outcome positive.

Powerful patient stories stand in contrast to a decision-making framework that explicitly dehumanises their lived experience. The need for 'decency and compassion'. Week one of Senate Estimates, the challenge of saying one thing publicly and something else privately, and a Budget that revealed so much about what is coming.

In this week's episode, the focus is on the latest example of no progress on reform, the mindset and intransigence it reveals, the repeated pattern, and the early evidence that it would always end this way. Can it be an opportunity? Next week's Budget is upon us, and the discussion focuses on what to look for, that just because it is not in there, does not mean it is not in there, and why gaining any cut-through will be a real challenge.

Another significant speech for the health portfolio that highlights the reform challenge and the importance of choices. A review announced in 2021 without an official response, and the reform of a major program announced with enabling legislation to be tabled next month. It's all about choices and priorities. Also, official recognition of discussions about managing a more assertive US on medicines pricing. What does it really mean?

Australia’s health system is overly bureaucratic, opaque, and misaligned, with reforms like the HTA Review slowing access rather than improving it. Decision-making prioritises institutional processes over patients, who remain largely excluded despite bearing the consequences. The system is based on a transactional model, and without genuine patient-led change, core structural problems will continue.

A powerful patient story was overshadowed by a mindset that expects patients to simplify their needs and accept delays. Some proposed reforms risk entrenching these problems, while claims of having a 'world-class system' gaslight patients and seek to shut down scrutiny. This is about power. Institutions hold it, and patients are expected to adapt, meaning they must not relent in their push for change.

In this episode, we examine funding uncertainty for genomic profiling through OMICO, structural tensions within the PBS and pharmaceutical supply chain, and broader concerns about how political and financial incentives shape health policy and budget decisions. The episode concludes with an uncomfortable discussion of recent public commentary on hostility against some communities (trigger warning).

Reflect on Susan Ley’s legacy as a former health minister, especially the 2015 PBS Access and Sustainability Package. She was treated rudely and unfairly, and that meaningful ecosystem reform has since stalled. Critique Senate Estimates, noting that departmental witnesses were evasive and overly defensive, with patients largely absent from the conversation. The discussion expands to reform and the lack of patient rights. Also note the troubling political rhetoric about medical informati...

The Government has announced an additional $25 billion for public hospitals over five years, representing close to two PBSs, while NDIS spending is still rising by $1 billion every few months. Can anyone seriously still argue that there is no new money available to invest in medicines?

Not for the first time, some Australian politicians are in trouble over their use of very generous travel entitlements. We discuss why it matters for patients and why the claim that they are acting within the rules does not stack up.

In this week’s Dispatched Podcast, we unpack the AI Health Summit and agree it revealed a gap between institutional caution and the real-world pace of its adoption. The practical reality of the proposed ban on genetic testing for life insurance, the self-limiting nature of Australia’s health reform processes, the status quo bias, and the absence of any genuine patient-centred purpose in current settings. We also discuss productivity, a critical roundtable, access inequities and the opportunit...